Nalaganje...
Targets of opportunity for precision medicine
In this issue of Blood, Schinke et al have identified a higher expression of CXCR2 in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) stem cells than in normal hematopoietic stem cells (HSCs) and demonstrated preclinical therapeutic proof of principle.(1)
Shranjeno v:
| izdano v: | Blood |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4432001/ https://ncbi.nlm.nih.gov/pubmed/25977578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-04-638270 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|